These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19078483)

  • 21. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The allopurinol hypersensitivity syndrome.
    Pluim HJ; van Deuren M; Wetzels JF
    Neth J Med; 1998 Mar; 52(3):107-10. PubMed ID: 9599967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exacerbation of allopurinol-induced drug reaction with eosinophilia and systemic symptoms by teicoplanin: A case report.
    Taghvaye Masoumi H; Hadjibabaie M; Zarif-Yeganeh M; Arasteh O
    J Clin Pharm Ther; 2017 Oct; 42(5):642-645. PubMed ID: 28556959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allopurinol-induced DRESS syndrome.
    Markel A
    Isr Med Assoc J; 2005 Oct; 7(10):656-60. PubMed ID: 16259349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    Gröbner W; Walter-Sack I; de Vries JX
    Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing new-onset gout in pediatric renal transplant recipients: when, how, to what extent.
    Assadi F
    J Nephrol; 2013; 26(4):624-8. PubMed ID: 22941874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Allopurinol-induced hypersensitivity syndrome].
    Kinyó A; Lakatos A; Varga A; Gyulai R; Varga E; Bata-Csörgő Z; Kemény L
    Orv Hetil; 2012 Apr; 153(15):586-91. PubMed ID: 22472359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease.
    Chao SC; Yang CC; Lee JY
    Ann Pharmacother; 2005 Sep; 39(9):1552-6. PubMed ID: 16076905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperuricemia and gout.
    Sloan RW
    J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allopurinol hypersensitivity syndrome: Liver transplantation after treatment of asymptomatic hyperuricaemia].
    Miederer SE; Miederer KO
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2537-40. PubMed ID: 25423467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.
    Min HK; Lee B; Kwok SK; Ju JH; Kim WU; Park YM; Park SH
    Korean J Intern Med; 2015 Jul; 30(4):521-30. PubMed ID: 26161019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
    Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
    Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity.
    Gillott TJ; Whallett A; Zaphiropoulos G
    Rheumatology (Oxford); 1999 Jan; 38(1):85-6. PubMed ID: 10334688
    [No Abstract]   [Full Text] [Related]  

  • 38. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol.
    Richette P; Bardin T
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):338-42; quiz 343. PubMed ID: 16932713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.